Pulmatrix EPS - Earnings per Share 2014-2022 | PULM

Pulmatrix eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Pulmatrix Annual EPS
2021 $-8.63
2020 $-13.43
2019 $-24.60
2018 $-99.60
2017 $-186.40
2016 $-376.00
2015 $-646.00
2014 $-6,904.00
2014 $-765.00
2013 $0.00
2013 $-130.00
2012 $-130.00
Pulmatrix Quarterly EPS
2022-03-31 $-1.51
2021-12-31 $-2.45
2021-09-30 $-3.00
2021-06-30 $-1.40
2021-03-31 $-1.78
2020-12-31 $-1.63
2020-09-30 $-6.20
2020-06-30 $-1.00
2020-03-31 $-4.60
2019-12-31 $2.00
2019-09-30 $-3.60
2019-06-30 $-8.20
2019-03-31 $-14.80
2018-12-31 $-4.40
2018-09-30 $-20.60
2018-06-30 $-26.80
2018-03-31 $-47.80
2017-12-31 $-42.40
2017-09-30 $-44.00
2017-06-30 $-58.00
2017-03-31 $-42.00
2016-12-31 $-134.00
2016-09-30 $-42.00
2016-06-30 $-124.00
2016-03-31 $-76.00
2015-12-31 $2,486.00
2015-09-30 $-68.00
2015-06-30 $-1,154.00
2015-03-31 $-1,910.00
2014-12-31 $-175.00
2014-09-30 $-11,920.00
2014-06-30 $-442.00
2014-03-31 $-230.00
2013-12-31 $-165.00
2013-09-30 $-250.00
2013-06-30 $-120.00
2013-03-31 $-115.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.005B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00